RANI
HEALTHCARERani Therapeutics Holdings Inc Class A
Live · NASDAQ · May 9, Close
What's Moving RANI Today?
No stock-specific AI insight has been generated for RANI yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$0.96
Fundamentals
Trading
RANI News
20 articles- This Rani Therapeutics Holdings Insider Increased Their Holding By 9,754% Last YearYahoo Finance·May 8, 2026
- Rani Therapeutics Appoints Dr. Sara Kenkare-Mitra as Strategic Advisor to Advance Platform and Clinical StrategyYahoo Finance·Apr 9, 2026
- Companies Like Rani Therapeutics Holdings (NASDAQ:RANI) Are In A Position To Invest In GrowthYahoo Finance·Mar 28, 2026
- Rani Therapeutics Q4 Earnings Call HighlightsMarketbeat·Mar 26, 2026
- Rani Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results; Provides Corporate UpdateYahoo Finance·Mar 26, 2026
- Rani Therapeutics Appoints Jesper Høiland as Head of Strategy to Advance Corporate and Pipeline PrioritizationGlobeNewswire Inc.·Mar 25, 2026
- Rani Therapeutics to Report Fourth Quarter and Full Year 2025 Financial ResultsYahoo Finance·Mar 19, 2026
- Rani Therapeutics Announces the Promotion of Alireza Javadi, Ph.D. to Chief Technical OfficerYahoo Finance·Jan 28, 2026
- Largest borrow rate increases among liquid namesYahoo Finance·Jan 24, 2026
- Retail investors account for 65% of Rani Therapeutics Holdings, Inc.'s (NASDAQ:RANI) ownership, while private equity firms account for 17%Yahoo Finance·Jan 23, 2026
- Rani Therapeutics Initiates Phase 1 Study of RT-114 RaniPill® for the Treatment of Obesity in Collaboration with ProGenYahoo Finance·Jan 8, 2026
- Rani Therapeutics to Participate in the Evercore Healthcare ConferenceYahoo Finance·Nov 24, 2025
- RANI: Third Quarter ResultsYahoo Finance·Nov 10, 2025
- Rani Therapeutics Reports Third Quarter 2025 Financial Results; Provides Corporate UpdateYahoo Finance·Nov 6, 2025
- Rani Therapeutics to Present Preclinical Data on Oral Delivery of Semaglutide via the RaniPill® Capsule at ObesityWeek® 2025Yahoo Finance·Oct 30, 2025
- H.C. Wainwright Initiates Rani Therapeutics (RANI) with Buy and $11 PT on RaniPill PotentialYahoo Finance·Oct 26, 2025
- Rani Therapeutics Announces the Appointments of Abe Bassan and Vasudev Bailey, Ph.D. to Board of DirectorsYahoo Finance·Oct 23, 2025
- Rani Therapeutics Announces Closing of Oversubscribed $60.3 Million Private Placement Priced At-the-Market under Nasdaq RulesYahoo Finance·Oct 23, 2025
- RANI: Chugai Deal AnnouncedYahoo Finance·Oct 20, 2025
- Trending tickers: Apple, Beyond Meat, Rani Therapeutics, BitMine and B&MYahoo·Oct 20, 2025
All 20 articles loaded
Price Data
52-Week Range
$0.96
Fundamentals
Trading
About Rani Therapeutics Holdings Inc Class A
Rani Therapeutics Holdings Inc. is a pioneering biotechnology firm that revolutionizes injectable therapeutic delivery through its proprietary RaniPill™ technology, enabling the oral administration of biologics. This innovative platform not only enhances patient adherence but also improves treatment outcomes, effectively addressing critical gaps in the healthcare landscape. With a diverse pipeline targeting various therapeutic areas, Rani Therapeutics is well-positioned to disrupt conventional drug delivery methods while leveraging the increasing demand for non-invasive treatment solutions. Furthermore, the company's strategic collaborations and strong emphasis on research and development highlight its potential for substantial growth and meaningful contributions to the pharmaceutical sector.